MedPath

A multicenter randomized controlled trial for Shi-Xiao-San Powder and Er-Zhi-Wan Pill in the treatment of primary biliary cirrhosis

Phase 1
Recruiting
Conditions
primary biliary cirrhosis
Registration Number
ITMCTR1900025303
Lead Sponsor
onghua Hospital, Shanghai University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) signing the informed consent;
(2) male or female aged 18-65 years;
(3) the syndrome differentiation of traditional Chinese medicine is liver kidney yin deficiency, blood stasis blocking collaterals;
(4) patients whose clinical diagnosis of Western medicine conforms to the PBC diagnostic standard and belongs to stage II and III;

Exclusion Criteria

(1) Combined with drug-induced liver injury, autoimmune hepatitis A, B, C, e, etc.;
(2) patients with serious primary diseases of heart, brain, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract, or psychosis;
(3) creatinine (CR) is higher than the upper limit of normal value;
(4) those who use drugs to lose weight;
(5) an alcoholic or drug addict;
(6) pregnant women, lactating women or those who prepare for pregnancy in the near future and those who use estrogen for contraception;
(7) those who are allergic to a variety of drugs, this medicine or its components;
(8) the patient is in critical condition, and it is difficult to make accurate evaluation on the effectiveness and safety of the new drug;
(9) patients are not willing to cooperate.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
AMA;APRI;AMA-M2;Clinical symptom score ;Clinical efficiency;GLOBE-Score;Fibrotouch;Four items of liver fibrosis ;liver function;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath